Literature DB >> 2820632

Limiting dilution analysis of specific in vitro anti-herpes simplex virus antibody production by human lymphocytes.

M Yasukawa1, Y Kobayashi.   

Abstract

An enzyme linked immunosorbent assay (ELISA) system to study specific anti-herpes simplex virus (HSV) antibody production in vitro by human peripheral blood mononuclear cells (PBMC) has been developed. HSV specific antibody production was detected in culture supernatants of PBMC from HSV seropositive healthy individuals by stimulating with optimal concentrations of HSV antigen without mitogens. To investigate the specificity of the resulting antibody, a limiting dilution analysis was performed as follows. PBMC from HSV-1 seropositive and HSV-2 seronegative individuals were stimulated by wild type HSV-1 (KOS), glycoprotein C deletion mutant of HSV-1 (MP), and wild type HSV-2 (186), and the precursor frequencies of B cells which produce antibodies to HSV-1 (KOS), HSV-1 (MP) and HSV-2 (186) were then estimated. When PBMC from five individuals were stimulated by HSV-1 (KOS), the estimated precursor frequencies of B cells which produced antibodies to HSV-1 (KOS), HSV-1 (MP), and HSV-2 (186) were 1/79,000 to 1/37,000, 1/104,000 to 1/52,000. and 1/78,000 to 1/101,000, respectively. On the other hand, when PBMC were stimulated by HSV-1 (MP) and HSV-2 (186), the precursor frequencies of B cells which produced antibody to HSV-1 (KOS) were the same as those to HSV-1 (MP) and HSV-2 (186), respectively. By using the experimental systems reported here, it became possible to determine clearly the immune status to HSV type-specific and type-common antigens and to each viral glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820632      PMCID: PMC1542684     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells.

Authors:  P G Spear
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

2.  Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide.

Authors:  M A Pellegrino; S Ferrone; M P Dierich; R A Reisfeld
Journal:  Clin Immunol Immunopathol       Date:  1975-01

3.  Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization.

Authors:  R H Stevens; A Saxon
Journal:  J Clin Invest       Date:  1978-12       Impact factor: 14.808

4.  Isolation, complementation and preliminary phenotypic characterization of temperature-sensitive mutants of herpes simplex virus type 2.

Authors:  J Esparza; D J Purifoy; P A Schaffer; M Benyesh-Melnick
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

5.  Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpesvirion.

Authors:  P G Spear; B Roizman
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

6.  A search for viruses in smegma, premalignant and early malignant cervical tissues. The isolation of Herpesviruses with distinct antigenic properties.

Authors:  W E Rawls; D Laurel; J L Melnick; J M Glicksman; R H Kaufman
Journal:  Am J Epidemiol       Date:  1968-05       Impact factor: 4.897

7.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.

Authors:  C Taswell
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

8.  Specific in vitro antibody response to influenza virus by human blood lymphocytes.

Authors:  R E Callard
Journal:  Nature       Date:  1979-12-13       Impact factor: 49.962

9.  Type-common and type-specific monoclonal antibody to herpes simplex virus type 1.

Authors:  L Pereira; T Klassen; J R Baringer
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

10.  Activation of human B lymphocytes. I. Direct plaque-forming cell assay for the measurement of polyclonal activation and antigenic stimulation of human B lymphocytes.

Authors:  A S Fauci; K R Pratt
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.